Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
- Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trial
- Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2
- Sandoz continues to build its biosimilars portfolio to increase patient access to high-quality, affordable biologics and generate savings for health systems
Basel, May 25, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Medicines Agency (EMA) has accepted the marketing authorization applications (MAA) for proposed biosimilar denosumab for regulatory review.
The two applications include all indications covered by the reference medicines Prolia® (denosumab)* and Xgeva® (denosumab)*, respectively, for treating a variety of conditions, including osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that have spread to the bone, and giant cell tumor of the bone.1,2
“Sandoz is one of the first to have its applications for a proposed biosimilar denosumab accepted by the EMA. If approved, this has the potential to provide people living with osteoporosis and cancer of the bone or bone metastasis access to a cost-effective and high-quality treatment option.” said Florian Bieber, Development Platform Head Biopharmaceuticals and Chief Medical Officer, Sandoz. “This news follows the recent application acceptance by the US Food and Drug Administration and supports our continued commitment to providing expanded access to life-changing treatments, while also helping over-burdened healthcare systems generate savings.”
Approximately 500 million men and women worldwide may be affected by osteoporosis, which causes 8.9 million fractures annually – or one fracture every three seconds.3 By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 1990.3 Prevalence of skeletal related complications in cancer is estimated to be as high as 63% for breast cancer, 59% for lung cancer and 52% for prostate cancer. Skeletal related complications in cancer are associated with loss of mobility and social functioning, reduced quality of life, increased health care expenditure and worse survival.4,5,6
The EMA applications are based on a comprehensive analytical and clinical data package, comprised of data from a Phase I PK/PD similarity study in healthy volunteers and the integrated Phase I/III ROSALIA study. The data package confirmed the denosumab biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity in the respective study populations; and contributes to the demonstration of similarity, which is the basis for use in all indications for which Xgeva and Prolia are approved.
Sandoz is committed to helping millions of patients sustainably and affordably access critical and potentially life-changing biologic medicines across a range of areas including immunology, oncology, supportive care and endocrinology. It has a leading global portfolio with eight marketed biosimilars and a further 24 assets in various stages of development. Since launching the first biosimilar in Europe in 2006, Sandoz has proven biosimilars create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels innovation and development of new and enhanced treatments in areas of unmet need.
Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue).1 By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions.7
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
- European Medicines Agency (EMA). Prolia® (Denosumab): Prescribing Information. Available from: https://www.ema.europa.eu/en/documents/product-information/prolia-epar-product-information_en.pdf [Last accessed: May 2023].
- European Medicines Agency (EMA). Xgeva® (Denosumab): Prescribing Information. Available from: https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf [Last accessed: May 2023].
- International Osteoporosis Foundation. Facts and Statistics. Available from: https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Last accessed: May 2023].
- Bhowmik D. et al. Current Medical Research and Opinion, 35:3, 513-523.
- Cadieux B. et al. Journal of Bone Oncology, 2022, 33: 1-13.
- Coleman R. et al. Bone health in cancer: ESMO Clinical Practice Guidelines, 2020.
- Amgen Europe B.V. Xgeva® (Denosumab): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf [Last accessed: May 2023].
*Prolia® and Xgeva® are registered trademarks of Amgen Inc.
# # #
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.
Sandoz on social media:
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
# # #
|Sandoz Global Communications|
|Chris Lewis||+49 174 244 9501||Leslie Pott||+1 609 627 5287|
|Novartis Media Relations|
|Richard Jarvis||+41 79 584 2326||Julie Masow||+1 862 579 8456|
|+41 79 619 2035|
|Novartis Investor Relations|
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 345 4440|
|Nicole Zinsli-Somm||+41 61 324 3809||Parag Mahanti||+1 973 876 4912|
|Isabella Zinck||+41 61 324 7188|
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Aktietilbagekøb i Spar Nord Bank – transaktioner i uge 226.6.2023 09:20:19 CEST | pressemeddelelse
Selskabsmeddelelse nr. 36 Spar Nord offentliggjorde i selskabsmeddelelse nr. 8 2023 et aktietilbagekøbsprogram på op til 300 mio. kr. Aktietilbagekøbet blev indledt 13. februar 2023. Aktietilbagekøbet sker med henblik på at nedsætte bankens aktiekapital med de under programmet købte aktier, og foretages i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 (”Markedsmisbrugsforordningen”). Under aktietilbagekøbsprogrammet er der i uge 22 gennemført følgende transaktioner: Antal aktierGennemsnitlig købskursTransaktionsværdi (DKK)Akkumuleret fra sidste meddelelse1.170.000130.379.53029. maj 202330. maj 202315.000103,681.555.20031. maj 202317.000102,201.737.40001. junij 202315.000103,681.555.20002. juni 202315.000105,841.587.600I alt uge 2262.0006.435.400I alt akkumuleret 1.232.000136.814.930 Efter de foranstående transaktioner ejer Spar Nord i alt 1.403.400 egne aktier svarende til 1,16 pct. af bankens aktiekapital. Spørgsmål i forbindelse med denne meddelelse kan rettes
Share buybacks in Spar Nord Bank – transactions in week 226.6.2023 09:20:19 CEST | Press release
Company announcement no. 36 In company announcement no. 8 2023, Spar Nord announced a share buyback programme of up to DKK 300 million. The share buyback was initiated on 13 February 2023. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 22, the following transactions were made under the share buyback programme. Number of sharesAverage purchase priceTransaction value (DKK)Accumulated from from last announcement1,170,000130,379,53029. May 202330. May 202315,000103.681,555,20031. May 202317,000102.201,737,40001. June 202315,000103.681,555,20002. June 202315,000105.841,587,600Total week 2262,0006,435,400Total accumulated 1,232,000136,814,930 Following the above transactions, Spar Nord holds a total of 1,403,400 treasury shares, equal to 1.16 % of the Bank’s share capital, Please direct any questions re
Kalmar and Port of Tauranga continue two decades of collaboration with new hybrid straddle carrier order6.6.2023 09:15:00 CEST | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 6 JUNE 2023 AT 10.15 AM (EEST) Kalmar, part of Cargotec, has secured a large order from long-term customer the Port of Tauranga in New Zealand for four Kalmar hybrid straddle carriers. The order was booked in Cargotec's Q2 2023 order intake, with delivery scheduled for Q4 of 2023. The Port of Tauranga, located on New Zealand’s North Island, is the country’s largest container terminal and its premier freight gateway, handling around 25 million tons of cargo and 1.2 million TEU a year. The port boasts significant land holdings and unrivalled sea, road and rail connections, and it has invested significant capital in recent years to enable it to process the largest container vessels visiting New Zealand today. Its equipment fleet already includes a number of Kalmar straddle carriers, including three hybrid models purchased in 2020. Dan Kneebone, Property & Infrastructure Manager, Port of Tauranga: “We purchased our first Kalmar straddle carriers back in
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 20236.6.2023 09:00:00 CEST | Press release
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their automated workflow solutions for streamlining discovery workflows in antibody and therapeutics development at Antibody Engineering and Therapeutics, Europe in Amsterdam, The Netherlands. In addition to the exhibition, Jason Lehmann, PhD Senior Product Marketing Manager at Telesis Bio will present “The BioXp® System: Accelerating Hit-to-Lead Discovery by Breaking Through Critical Synthesis Bottlenecks” in the opening day session. The award winning BioXp® system and associated BioXp De novo kits and BioXp Select kits enable push-button, automated synthesis of gene fragments, clones, variant libraries and mRNA from input sequence or existing DNA. In May, Telesis Bio also introduced their first automated NG
Anmodning om suspension for afdelinger under Investeringsforeningen BankInvest6.6.2023 09:00:00 CEST | pressemeddelelse
København K, June 06, 2023 (GLOBE NEWSWIRE) -- På grund af lokale lukkedage i de underliggende markeder anmodes om suspension af nedenstående afdelinger. AfdelingISINShort nameEuropa Small Cap Aktier ADK0060571362BAIESCAEmerging Markets Aktier ADK0060516854BAIEMAA Hvis der er spørgsmål, kontakt da Teamleder for Fund Valuation, Peter Akstrup, telefon 77 30 90 31. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør